MP1032 Treatment in Patients With Moderate to Severe COVID-19
NCT ID: NCT04932941
Last Updated: 2023-06-29
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
132 participants
INTERVENTIONAL
2021-10-19
2022-09-05
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase IIa Randomized Placebo Controlled Clinical Study of Codivir in Hospitalized Patients with Moderate COVID-19
NCT05218356
Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19
NCT04336904
Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19
NCT04632706
A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care
NCT05195749
The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection
NCT04766931
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MP1032
Participants will receive MP1032 300 milligrams (mg) twice daily (BID) with hospital selected SoC for 28 days.
MP1032
Hard gelatin capsules for oral administration.
Placebo
Participants will receive placebo matched to MP1032 with hospital selected SoC for 28 days.
Placebo
Placebo capsules matched to MP1032 for oral administration.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MP1032
Hard gelatin capsules for oral administration.
Placebo
Placebo capsules matched to MP1032 for oral administration.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant has the presence of any symptom(s) suggestive of moderate or severe systemic illness with COVID-19
Exclusion Criteria
* Participant has a diagnosis of asymptomatic COVID-19, mild COVID-19, or critical COVID-19 on Day 1
* Participant has a documented medical history of infection with hepatitis A, B, C, or with human immunodeficiency virus (with a detectable viral load and CD4 count \<500 cells per micro liter), or a documented active infection with tuberculosis.
* The Participant has clinically significant electrocardiogram (ECG) abnormalities at screening
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Syneos Health
OTHER
MetrioPharm AG
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Snake River Research PLLC
Idaho Falls, Idaho, United States
Richmond University Medical Center
Staten Island, New York, United States
MHAT Blagoevgrad AD
Blagoevgrad, , Bulgaria
MHAT Sv. Ivan Rilski Kozloduy
Kozloduy, , Bulgaria
MHAT Dr. Stamen Iliev AD
Montana, , Bulgaria
SHATPD Pernik EOOD
Pernik, , Bulgaria
MHAT Dr. Ivan Seliminski AD
Sliven, , Bulgaria
Umhatem"N.I.Pirogov"
Sofia, , Bulgaria
SHATPPD Sata Zagora EOOD
Stara Zagora, , Bulgaria
Centre Hospitalier Victor Dupouy
Argenteuil, , France
CHU de Grenoble Alpes
Grenoble, , France
Centre Hospitalier Lyon Sud
Pierre-Bénite, , France
DE KK Infektológiai Klinika
Debrecen, , Hungary
Flor Ferenc Hospital of Pest County
Kistarcsa, , Hungary
Ospedale GB Morgagni
Forlì, , Italy
Ospedale SM Goretti
Latina, , Italy
ASST-FBF-SACCO - Ospedale Luigi Sacco
Milan, , Italy
IRCCS Ospedale San Raffaele
Milan, , Italy
Policlinico di Napoli
Napoli, , Italy
Ospedale "Santo Spirito! Pescara
Pescara, , Italy
Policlinico Agostino Gemelli
Roma, , Italy
Spitalul Clinic de Boli Infectioase si Tropicale "Dr. Victor Babes"
Bucharest, , Romania
Spitalul Municipal Caracal
Caracal, , Romania
Spitalul Clinic de Boli Infectioase "Sfanta Parascheva"
Iași, , Romania
Clinica Anestezie si Terapie Intensiva
Timișoara, , Romania
Hospital Clinic de Barcelona Hospital Clinic i Provincial
Barcelona, , Spain
Hospital Ramon y Cajal, Edificio Central
Madrid, , Spain
Hospital Clínico Universitario de Salamanca
Salamanca, , Spain
Hospital Universitario Marqués de Valdecilla/IDIVAL
Santander, , Spain
Hospital Universitario de Valme
Seville, , Spain
Hospital Álvaro Cunqueiro
Vigo, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-000344-21
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
MP1032-CT05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.